Patents Examined by Umamaheswari Ramachandran
  • (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
    Patent number: 11400075
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: August 2, 2022
    Assignee: ANNOVIS BIO, INC.
    Inventor: Maria Maccecchini
  • Treatment of allergic rhinitis using a combination of mometasone and olopatadine
    Patent number: 11400101
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: August 2, 2022
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Treatment of pain and/or pain related symptoms associated with dysmenorrhea
    Patent number: 11400059
    Abstract: The present disclosure relates to methods, compositions and products for treating pain, and/or pain related symptoms, associated with dysmenorrhea in a subject. In certain embodiments, the present disclosure provides a method of treating pain, and/or pain related symptoms, associated with dysmenorrhea in a subject, the method comprising intrauterine and/or vaginal administration to the subject of an effective amount of an agent that reduces activation of the innate immune system and thereby treating the pain and/or the pain related symptoms in the subject. Other embodiments are also disclosed.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: August 2, 2022
    Assignee: ALYRA BIOTECH PTY LTD
    Inventor: Susan Florence Evans
  • Treatment of disorders arising from genetic mutation
    Patent number: 11389419
    Abstract: A method for treatment of disorders arising due to mutation of one or more genes in humans. The method includes the step of orally administering a composition comprising L-carnitine tartrate, pyridoxal-5?-phosphate, and fumaric acid.
    Type: Grant
    Filed: July 5, 2021
    Date of Patent: July 19, 2022
    Inventor: Deborah Warner
  • Methods of regulating cannabinoid receptor activity-related disorders and diseases
    Patent number: 11389415
    Abstract: This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: July 19, 2022
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Secretary, Department of Health and Human Services
    Inventors: Irving W. Wainer, Michel Bernier, Rajib K. Paul
  • Cancer therapy
    Patent number: 11382903
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: July 12, 2022
    Assignee: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi, Mark Thomas McHale
  • (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
    Patent number: 11382893
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: July 12, 2022
    Assignee: ANNOVIS BIO, INC.
    Inventor: Maria Maccecchini
  • Drug combination for treatment of amyotrophic lateral sclerosis, preparation method and use thereof
    Patent number: 11376267
    Abstract: A drug combination for treatment of amyotrophic lateral sclerosis includes chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium, as well as pharmaceutically acceptable carriers, in which chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium are unit preparations having same or different specifications, that are simultaneously or separately administrated. The combination of chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium shows a synergistic effect on amyotrophic lateral sclerosis, thus provides a combination with excellent therapeutic effect on amyotrophic lateral sclerosis, which delays the progression of amyotrophic lateral sclerosis.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: July 5, 2022
    Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Jie Zhang, Xiaoguang Chen, Huarong Yang, Wenbin Li
  • (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
    Patent number: 11376238
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: July 5, 2022
    Assignee: ANNOVIS BIO, INC.
    Inventor: Maria Maccecchini
  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 11369606
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 28, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • Use of thyroid beta-agonists
    Patent number: 11351183
    Abstract: Methods useful for treating X-linked adrenoleukodystrophy are provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: June 7, 2022
    Assignees: Viking Therapeutics, Inc., Metabasis Therapeutics, Inc.
    Inventors: Brian Lian, Rochelle Hanley, Misha Dinerman, Mark Erion, Serge Boyer, Hongjian Jiang
  • Brain derived PPAR? ligands
    Patent number: 11344524
    Abstract: Methods of modulating peroxisome proliferator-activated receptor ? (PPAR?) activity in a cell in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR? ligand to the subject where the PPAR? ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT). Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR? ligand to the subject.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: May 31, 2022
    Assignee: RUSH UNIVERSITY MEDICAL CENTER
    Inventors: Kalipada Pahan, Avik Roy
  • Appetite suppressant compositions and methods thereof
    Patent number: 11344556
    Abstract: In various embodiments an appetite suppressant composition comprises at least one anorectic active ingredient (AAI); at least one of a nutritive substance, a controlled drug delivery agent (CDRA), and a cofactor; and optionally, an excipient. The AIA may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The CDRA may comprise a cellulosic. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: May 31, 2022
    Assignee: RED MOUNTAIN HOLDINGS, LLC
    Inventor: Suzanne Bentz
  • Compositions and methods to regulate hormonal cascades in stress disorders
    Patent number: 11337955
    Abstract: The invention is composition and methods that restore balance to the stress-related steroidal hormone cascade. Upon co-administration, the compounds of the invention restore balance to the cascade and promote or restore normal function in patients suffering from a disorder having a primary psychological stress component. The compositions include a selected combination of isoflavones, alpha lipoic acid, and L dopamine or a precursor thereof, and are preferably obtained from the natural sources disclosed herein. The uses of the invention include administration of the disclosed compositions to patients suffering from PTSD, fibromyalgia, endometriosis, and other disorders having a common chronic stress component.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: May 24, 2022
    Assignee: BIOMMUNITY, INC.
    Inventor: Paul G. Emerson
  • Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
    Patent number: 11337983
    Abstract: The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: May 24, 2022
    Inventors: Brunangelo Falini, Maria Paola Martelli
  • Dapsone formulations and methods of using same
    Patent number: 11337939
    Abstract: A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: May 24, 2022
    Assignee: Pulmonem Inc.
    Inventors: Houfar Sekhavat, Satish Asotra
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 11337927
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 24, 2022
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Compositions and methods for treating rosacea and acne
    Patent number: 11324691
    Abstract: Provided are compositions and methods for treating rosacea and acne. Specifically, a gel or foam composition having a tetracycline antibiotic and uses thereof for treating rosacea and acne are provided.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: May 10, 2022
    Assignee: Journey Medical Corporation
    Inventors: Dov Tamarkin, Meir Eini, Yohan Hazot, Mitchell Shirvan, Tal Hetzroni Kedem, Rita Keynan
  • Compositions and methods for treating ocular disorders
    Patent number: 11324722
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: May 10, 2022
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina deVries, David Jacobs
  • Preservatives for cosmetic, toiletry and pharmaceutical compositions
    Patent number: 11291204
    Abstract: A composition for and methods of preserving a topical cosmetic, toiletry or pharmaceutical formulation against microbiological contamination or growth are described in which the compositions used herein include at least one hydroxamic acid, salt or complex thereof, and the methods include addition of an effective amount of such compounds to a cosmetic, toiletry or pharmaceutical formulation. Compositions further including alkanediols and/or solubilizing agents in blends with hydroxamic acid are also described.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: April 5, 2022
    Assignee: INOLEX INVESTMENT CORPORATION
    Inventor: Daniel Winn